title: Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells.
abstract: Treatment of malignant disease with interleukin-2 and lymphokine-activated killer cells activates autoreactive T lymphocytes, stimulates release of cytokines and induces expression of HLA-class II antigens by tumour cells. We studied eight patients with hepatocellular carcinoma treated with a total of 16 courses of recombinant human interleukin-2 and lymphokine-activated killer cells and observed them for features of autoimmune thyroid disease. During the course of treatment there were significant decreases in total serum T4 and T3 and free thyroxine levels, but no change in TSH levels when all patients were analysed as a group. This was due to a number of factors including suppression of thyroid hormone release, haemodilution during interleukin-2 infusion and actual removal of thyroid hormones from the circulation during leukapheresis. Thyroid hormones returned to normal levels during resting period. One patient subsequently developed compensated hypothyroidism (normal total T4, total T3 and free T4 but elevated TSH) and four patients had features of 'sick euthyroid syndrome' (low total T4, total T3 or free T4 but normal TSH). None of the patients studied developed antibodies to thyroglobulin or microsomes. In contrast, no abnormality of thyroid function was seen in any of the nine subjects who received no active treatment. In conclusion, thyroid dysfunction was associated with immunotherapy of malignant disease with interleukin-2 and lymphokine-activated killer cells. This may arise from direct hormonal effects of the cytokines on thyroid hormone production.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital.
authors.forename: A W
authors.initials: AW
authors.lastname: Kung
authors.forename: C L
authors.initials: CL
authors.lastname: Lai
authors.forename: K L
authors.initials: KL
authors.lastname: Wong
authors.forename: C F
authors.initials: CF
authors.lastname: Tam
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008113:Liver Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects; D013959:Thyroid Diseases / Q000209:etiology* / Q000503:physiopathology; D013961:Thyroid Gland / Q000276:immunology / Q000503:physiopathology*
chemical_list: D001323:Autoantibodies; D007376:Interleukin-2; D011994:Recombinant Proteins